Article Text

Download PDFPDF

793 Combined administration of the dual A2aR/A2bR antagonist etrumadenant with a reduced chemotherapy regimen leads to enhanced tumor efficacy and survival
  1. Sachie Marubayashi,
  2. Dana Piovesan,
  3. Ferdie Soriano,
  4. Gonzalo Barajas,
  5. Ruben Flores,
  6. Janine Kline,
  7. Matthew J Walters and
  8. Daniel DiRenzo
  1. Arcus Biosciences, Inc, Hayward, CA, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Chemotherapy remains the standard of care for numerous cancer indications; however, in addition to having poor overall tolerability, a negative effect of such regimens is the extracellular release of adenosine triphosphate, which is rapidly converted to immunosuppressive adenosine by the enzymes CD39 and CD73. Extracellular adenosine drives immunosuppression by activating the A2aR and A2bR adenosine receptors on immune cells, thereby inhibiting their activity and enabling tumor growth and survival. We have previously shown that etrumadenant (etruma), a dual A2aR/A2bR antagonist, prevents adenosine-mediated immunosuppression in vitro and combines with immunogenic chemotherapy to enable greater control of mouse syngeneic tumors. In our current work, we sought to evaluate the ability of etruma to enhance the anti-tumor immune activity of priming doses of chemotherapy, compared to an extended chemotherapy regimen alone.

Methods Mice were inoculated with syngeneic cancer cells, 4T1 or AT3-OVA. Once tumors were established (50 or 100 mm3), mice were treated with doxorubicin (5 mg/kg, Q7D), alone or in combination with etruma (100 mg/kg BID). Gross anatomic, histological and flow cytometric analyses of CD8+ T cells were performed on tumor or lung tissue.

Results We have previously shown in AT3-OVA tumors that etruma combines with doxorubicin (dox) to provide greater tumor control and CD8+ T cell infiltration compared to dox alone. Building upon these data, we combined etruma with 2 or 4 doses of dox and found that addition of etruma significantly reduced tumor burden and increased survival in both dox dosing regimens. Etruma combined with 2 dox doses showed similar tumor control as 4 doses of dox alone (2 dose dox: 601 ± 79 mm3; 2 dose combo: 232 ± 25 mm3; 4 dose dox: 263 ± 26 mm3). Similar results were observed in 4T1 tumor-bearing mice, where etruma in combination with dox suppressed lung metastases after 2 doses of dox with no further improvement observed with a third dose of chemotherapy (lung mets per mouse: 3 dose dox: 41 ± 5; 2 dose combo: 16 ± 4; 3 dose combo: 12 ± 2). These data suggest that etruma sustains the immune response driven by the initial doses of chemotherapy leading to enhanced tumor control.

Conclusions Altogether, these data show that the combined treatment of chemotherapy with etruma leads to increased tumor control in multiple preclinical models and suggest that etruma combined with a reduced course of chemotherapy may have comparable activity as an extended chemotherapy dosing regimen.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.